Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Income Statement
Earnings Waterfall
Zhejiang Tianyu Pharmaceutical Co Ltd
Revenue
|
2.4B
CNY
|
Cost of Revenue
|
-1.6B
CNY
|
Gross Profit
|
852.2m
CNY
|
Operating Expenses
|
-792.7m
CNY
|
Operating Income
|
59.5m
CNY
|
Other Expenses
|
-148.4m
CNY
|
Net Income
|
-88.9m
CNY
|
Income Statement
Zhejiang Tianyu Pharmaceutical Co Ltd
Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||
Revenue |
1 116
N/A
|
1 149
+3%
|
1 188
+3%
|
1 201
+1%
|
1 226
+2%
|
1 309
+7%
|
1 467
+12%
|
1 666
+14%
|
1 799
+8%
|
2 046
+14%
|
2 111
+3%
|
2 181
+3%
|
2 464
+13%
|
2 532
+3%
|
2 587
+2%
|
2 778
+7%
|
2 623
-6%
|
2 523
-4%
|
2 545
+1%
|
2 536
0%
|
2 652
+5%
|
2 690
+1%
|
2 667
-1%
|
2 694
+1%
|
2 539
-6%
|
2 447
-4%
|
|
Gross Profit | |||||||||||||||||||||||||||
Cost of Revenue |
(695)
|
(714)
|
(747)
|
(772)
|
(829)
|
(862)
|
(884)
|
(949)
|
(921)
|
(975)
|
(941)
|
(964)
|
(1 103)
|
(1 132)
|
(1 258)
|
(1 444)
|
(1 477)
|
(1 571)
|
(1 638)
|
(1 690)
|
(1 861)
|
(1 957)
|
(2 076)
|
(1 978)
|
(1 756)
|
(1 595)
|
|
Gross Profit |
421
N/A
|
435
+3%
|
441
+1%
|
429
-3%
|
397
-7%
|
447
+13%
|
583
+30%
|
717
+23%
|
878
+22%
|
1 071
+22%
|
1 169
+9%
|
1 217
+4%
|
1 362
+12%
|
1 400
+3%
|
1 329
-5%
|
1 333
+0%
|
1 146
-14%
|
952
-17%
|
907
-5%
|
846
-7%
|
791
-7%
|
732
-7%
|
591
-19%
|
716
+21%
|
783
+9%
|
852
+9%
|
|
Operating Income | |||||||||||||||||||||||||||
Operating Expenses |
(256)
|
(256)
|
(279)
|
(289)
|
(311)
|
(340)
|
(369)
|
(380)
|
(408)
|
(446)
|
(478)
|
(484)
|
(529)
|
(566)
|
(585)
|
(626)
|
(651)
|
(656)
|
(703)
|
(706)
|
(661)
|
(652)
|
(645)
|
(716)
|
(783)
|
(793)
|
|
Selling, General & Administrative |
(260)
|
(254)
|
(208)
|
(250)
|
(228)
|
(243)
|
(275)
|
(281)
|
(311)
|
(331)
|
(353)
|
(368)
|
(410)
|
(435)
|
(393)
|
(433)
|
(439)
|
(447)
|
(452)
|
(476)
|
(441)
|
(422)
|
(389)
|
(414)
|
(421)
|
(396)
|
|
Research & Development |
0
|
(9)
|
(59)
|
0
|
0
|
(39)
|
(69)
|
(67)
|
(92)
|
(103)
|
(97)
|
(114)
|
(130)
|
(153)
|
(158)
|
(202)
|
(224)
|
(223)
|
(203)
|
(231)
|
(223)
|
(231)
|
(204)
|
(233)
|
(248)
|
(246)
|
|
Depreciation & Amortization |
0
|
0
|
(18)
|
0
|
0
|
0
|
(30)
|
0
|
0
|
0
|
(43)
|
0
|
0
|
0
|
(59)
|
0
|
0
|
0
|
(66)
|
0
|
0
|
0
|
(78)
|
0
|
0
|
0
|
|
Other Operating Expenses |
3
|
7
|
7
|
(39)
|
(83)
|
(59)
|
6
|
(32)
|
(5)
|
(11)
|
15
|
(1)
|
12
|
21
|
24
|
9
|
13
|
14
|
18
|
1
|
2
|
1
|
27
|
(69)
|
(115)
|
(151)
|
|
Operating Income |
164
N/A
|
180
+9%
|
163
-9%
|
140
-14%
|
86
-38%
|
107
+24%
|
214
+100%
|
338
+58%
|
470
+39%
|
625
+33%
|
691
+11%
|
734
+6%
|
833
+14%
|
834
+0%
|
744
-11%
|
707
-5%
|
495
-30%
|
296
-40%
|
204
-31%
|
140
-31%
|
130
-8%
|
80
-38%
|
(53)
N/A
|
0
N/A
|
0
+46%
|
59
+49 864%
|
|
Pre-Tax Income | |||||||||||||||||||||||||||
Interest Income Expense |
(20)
|
(26)
|
(27)
|
(27)
|
(12)
|
(20)
|
(19)
|
(16)
|
(26)
|
(5)
|
(2)
|
(2)
|
4
|
9
|
32
|
30
|
45
|
46
|
36
|
42
|
17
|
(17)
|
(48)
|
(74)
|
(115)
|
(125)
|
|
Non-Reccuring Items |
(2)
|
(2)
|
(17)
|
(6)
|
0
|
0
|
(5)
|
0
|
0
|
0
|
(4)
|
0
|
(1)
|
(1)
|
(5)
|
0
|
0
|
0
|
(16)
|
0
|
0
|
0
|
(8)
|
(0)
|
(0)
|
(0)
|
|
Total Other Income |
1
|
0
|
(0)
|
(1)
|
(2)
|
(3)
|
(2)
|
(7)
|
(6)
|
(5)
|
(1)
|
(5)
|
(6)
|
(10)
|
(1)
|
(6)
|
(7)
|
(4)
|
(6)
|
(21)
|
(22)
|
(21)
|
(0)
|
(10)
|
(10)
|
(8)
|
|
Pre-Tax Income |
143
N/A
|
151
+6%
|
119
-21%
|
107
-10%
|
73
-32%
|
84
+16%
|
189
+125%
|
315
+66%
|
439
+39%
|
615
+40%
|
684
+11%
|
727
+6%
|
830
+14%
|
832
+0%
|
769
-8%
|
731
-5%
|
533
-27%
|
338
-37%
|
218
-35%
|
162
-26%
|
125
-23%
|
42
-66%
|
(111)
N/A
|
(84)
+24%
|
(124)
-49%
|
(74)
+40%
|
|
Net Income | |||||||||||||||||||||||||||
Tax Provision |
(20)
|
(24)
|
(19)
|
(17)
|
(7)
|
(11)
|
(26)
|
(43)
|
(61)
|
(86)
|
(98)
|
(103)
|
(118)
|
(113)
|
(102)
|
(97)
|
(67)
|
(43)
|
(14)
|
(6)
|
(6)
|
(5)
|
(8)
|
(20)
|
(21)
|
(15)
|
|
Income from Continuing Operations |
123
|
127
|
100
|
89
|
65
|
73
|
164
|
272
|
377
|
529
|
586
|
624
|
713
|
719
|
667
|
634
|
466
|
295
|
205
|
156
|
119
|
37
|
(119)
|
(103)
|
(146)
|
(89)
|
|
Net Income (Common) |
123
N/A
|
127
+3%
|
100
-21%
|
89
-11%
|
65
-27%
|
73
+12%
|
164
+124%
|
272
+66%
|
377
+39%
|
529
+40%
|
586
+11%
|
624
+7%
|
713
+14%
|
719
+1%
|
667
-7%
|
634
-5%
|
466
-26%
|
295
-37%
|
205
-31%
|
156
-24%
|
119
-24%
|
37
-69%
|
(119)
N/A
|
(103)
+13%
|
(146)
-41%
|
(89)
+39%
|
|
EPS (Diluted) |
0.92
N/A
|
0.71
-23%
|
0.69
-3%
|
0.49
-29%
|
0.35
-29%
|
0.39
+11%
|
0.91
+133%
|
1.49
+64%
|
2.07
+39%
|
2.9
+40%
|
3.22
+11%
|
3.44
+7%
|
3.91
+14%
|
3.95
+1%
|
3.66
-7%
|
3.22
-12%
|
1.34
-58%
|
0.83
-38%
|
0.59
-29%
|
0.45
-24%
|
0.34
-24%
|
0.11
-68%
|
-0.34
N/A
|
-0.29
+15%
|
-0.41
-41%
|
-0.24
+41%
|